Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Item
http://www.wikidata.org/entity/Q26745838
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.The Epstein-Barr virus DNA load in the peripheral blood of transplant recipients does not accurately reflect the burden of infected cells.Immunotherapy for transplantation-associated viral infections.Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD.The impact of targeting repetitive BamHI-W sequences on the sensitivity and precision of EBV DNA quantification.B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2.Central nervous system complications after allogeneic hematopoietic stem cell transplantation.Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.Reply to: Role of PET-CT in management of post-transplant lymphoproliferative disorder: Preliminary experience on the use of PET/CT in the management of pediatric post-transplant lymphoproliferative disorder.Role of PET-CT in management of posttransplant lymphoproliferative disorder.Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
P2860

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Item
http://www.wikidata.org/entity/Q26745838
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@ast
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@en
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@nl
type
label
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@ast
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@en
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@nl
prefLabel
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@ast
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@en
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Management of Epstein-Barr Vir ...... n Leukemia (ECIL-6) guidelines
@en
P2093
P2860
P304
P31
P356
10.3324/HAEMATOL.2016.144428
P407
P433
P478
P50
P577
P698
P921
P932